PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE no persons are required to respond to a collection of information unless it contains a valid OMB control number Under the Paperwork

Substitute for Form 1449/A/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

of 2

Cor	Complete if Known						
Application Number	10/621,113						
Filing Date	July 16, 2003						
First Named Inventor	J. David Lambeth et al.						
Group Art Unit	1614- 1652						
Examiner Name	Unknown T. Saidha						
Attorney Docket Number	43150/287577 (05501-0202)						

	U.S. PATENT DOCUMENTS									
Examiner Cite Kind Code ² Number Name of Patentee or Applicant of Cited Document MM-DD-YYYY Figures Appear										
1. 6,620,603			\neg	LAMBETH et al.	09-16-2003	H35/189	_			
<u> </u>		<u> </u>	1	FOR	EIC	ON PATENT DOCUMEN	TS			
Examiner		Foreign Patent Document			_	Name of Datastas as	Date of Publication	Pages, Columns, Lines,	\Box	
Initials	Cite No.1	Office ³	Number ⁴	Kind Code ³ (if known)		Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	16	
2. WO 00/28031 A2					2	Emory University	05/18/2000			
30	3.	wo	01/087957	Α Α	.3	Emory University	11-22-2001			
200	4.	wo	02/081703	A	2	Emory University	10-17-2002		\square	

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS							
Exam Initia		Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²			
	5	5.	Burdon, R.H., "Superoxide and hydrogen peroxide in relation to mammalian cell				
	18	proliferation," Free Radical Biol. Med., Volume 18, No. 4, pp. 775-794 (1995).					
		6.	Cheng, G., et al., Gene, 269: pp. 131-140, May 16, 2001.				
		7.	Church, S.L., et al., "Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells," Proc. Natl. Acad. Sci. USA, Volume 90, pp. 3113-3117 (1993).				
		8.	Edens, W., et al., "Tyrosine cross-linking of extracellular matrix is catalyzed by Duox, a multidomain oxidase/peroxidase with homology to the phagocyte oxidase subunit gp91phox," J. Cell Biol., 154(4): pp. 879-91, August 20, 2001.				
		9.	9. Fernandez-Pol, J.A., et al., "Correlation between the loss of the transformed phenotype and an increase in superoxide dismutase activity in a revertant subclone of sarcoma virus-infected mammalian cells," Can. Res., Volume 42, pp. 609-617 (1982).				
		10.	Fukui, T., et al., "p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats," Circ. Res., Volume 80, No. 1, pp. 45-51 (1997).				
		11.	Griendling, K. K., et al., "Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells," Circ. Res., Vol. 74, No. 6, pp. 1141-1148 (1994).	,			
		12.	Irani, K., et al., "Mitogenic signaling mediated by oxidants in ras-transformed fibroblasts," Science, Vol. 275, No. 5306, pp. 1649-1652 (1997).				
		13.	Lambeth, J. D., et al., "Novel homologs of gp91phox," Trends Biochem. Sci., (10): pp. 459-61, October 25, 2000.				
		14.	Li, Y., et al., "Validation of lucigenin (Bis-N-methylacridinium) as a chemilumigenic probe for detecting superoxide anion radical production by enzymatic and cellular systems," J. Biol. Chem., Vol. 273, No. 4, pp. 2015-2023 (1998).				
5	CA	15.	Matsubara, T., et al., "Increased superoxide anion release from human endothelial cells in				

response to cytokines," J. Immun., Vol. 137, No. 10, pp. 3295-3298 (1986).

'Unique citation designation number. 'See attached Kinds of U.S. Patent Documents. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	Complete if Known							
Sub	stitute f	for Form	1449/A/PTO	Application Number	10/621,113			
	1	INFO	DRMATION DISCLOSURE	Filing Date	July 16, 2003			
	9	STA	TEMENT BY APPLICANT	First Named Inventor	J. David Lambeth et al.			
	· ·	• • • • •	(use as many sheets as necessary	Group Art Unit	1614 1652			
				Examiner Name	Unknown T. Saidh	a		
Sh	eet	2	of 2	Attorney Docket Number	43150/287577 (05501-0202))		
	OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS							
Exa	miner	Cite	Include name of the author (in CAPITAL I			T ²		
	tials	No.'		and/or country where published		<u> </u>		
1	æ	16.	Meier, B., et al., "Human fibroblasts					
	10	<u> </u>	interleukin-1 or tumor necrosis factor-α,'					
		17.	1 - 20-20, 2 : 5 :, 5 : 4 ::., 2004::24::61: 61: 61:		~ •			
			in rabbit aortic adventitia: Enhancemen		roc. Natl. Acad. Sci. USA,			
			Volume 94, No. 26, pp. 14483-14488 (19					
		18.	Oomman, 12. 14., or al., 1110 10103 of 11ya					
			activation of transcription factor NF-kB,					
	1	19.	Schreck, R., et al., "Reactive oxygen into					
			the activation of the NF-kB transcription	n factor and HIV-1," El	MBO J., Vol. 10, No. 8, pp.			
			2247-2258 (1991).	·				
		20.	Sundaresan, M., et al., "Requirement f					
			factor signal transduction," Science, Vol.					
		21.	Szatrowski, T.P., et al., "Production of la		en peroxide by human tumor			
			cells," Canc. Res., Vol. 51, No. 3, pp. 794					
-		22.	Uhlinger, D.J., "Nucleoside triphosph	•	1			
			phosphorylation in a cell-free system from	m human neutrophils,"	Vol. 266, No. 31, pp. 20990-			
\dashv		22	20997 (1991).	• • •				
		23.	Ushio-Fukai M., et al., "p22 ^{phox} is a					
ľ			NADH/NADPH oxidase system and					
-		24.	vascular smooth muscle cells," J. Biol. C			-		
1		24.	Yan, T., et al., "Manganese-containi	O 1	•			
- [,		phenotypic reversion in SV40-transforme	ed numan lung libroblas	its, Canc. Res., vol. 30, pp.			
 	000	25.	2864-2871 (1996). Yu, L., et al., Biosynthesis of the phage	roorde MADDU ovidees	autochrome h " I Die!	\vdash		
5	48	.د	Chem., Vol. 272, No. 43, pp. 27288-2729		c cylochrome 0558, J. B101.			
	+	ل ا	/ Ciloin., voi. 272, 140. 43, pp. 27286-2725	/ 7 (1 <i>771)</i> .		لـــــا		
Exa	miner	· · · · · ·	1 Swe	Date	6/3/05			

Considered

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Signature

Examiner's

Cite No.

OIPE
B MAY 0 6 2005
SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Country

Attorney Docket Number	6975-69498-03
Application Number	10/621,113
Filing Date	July 16, 2003
First Named Inventor	Lambeth
Art Unit	1652
Examiner Name	Tekchand

Name of

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee				
			·					
	FOREIGN PATENT DOCUMENTS							

Number

Publication Date

Initials*	(optional)]			Applicant or Patentee					
Se		PCT	WO01/75067	10/11/2001	HYSEQ, Inc.					
. 1										
l										
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS								
The		CHENG, Guangjie et al., Journal of Biological Chemistry, Vol. 279, No. 6, Feb. 6, 2004, pp. 4737-4742.								
		CHENG, Guangjie et al., Journal of Biological Chemistry, Vol. 279, No. 33, Aug. 13, 2004, pp. 34250-34255.								
		GEISZT, Miklos pp. 20006-20012		iological Chemistry,	Vol. 278, No. 22, May 30, 2003,					
The		TAKEYA, Ryu e pp. 25234-25246.		ological Chemistry, V	ol. 278, No. 27, July 4, 2003,					

EXAMINER SIGNATURE:	T.	Saidha	DATE CONSIDERED:	6/3/05
------------------------	----	--------	---------------------	--------

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

SAS:mlb 06/09/05 6975-69498-03 393828 · 02065US

		·	Attorney Docket Number	6975-69498-03			
			Application Number	10/621,113			
INFOR		N DISCLOSURE STATEMENT	Filing Date	July 16, 2003			
		BY APPLICANT	First Named Inventor	Lambeth			
		•	Art Unit	1652			
			Examiner Name	Tekchand Saidha			
Examiner's Initials*	Cite No. (optional)		HER DOCUMENTS				
JE		MALY et al., "Restitution of Supero Chronic Granulomatous Disease (A2 Transfection with p22phox cDNA," J.	77° ('CiD) desired D I L				
Ja		Flavocytochrome b ₅₅₉ Participating i "Peptide Walking," J. Biol. Chem., \	onal Domains in the p22 ^{pnox} to the Assembly of the NAD Vol. 277. No. 10, pp. 8421-8.	Subunit of PH Oxidase Complex by			
Ops		SUMIMOTO et al., "Role of Src hor phagocyte NADPH oxidase," Proc. I	nology 3 domains in assemb	ly and notivation of the			
1/8	9	PAULUS et al., "NAD(P)H oxidase: www.servier.com/pro/eardiologie/pd	A pernetrator of cardiovasc	ular damage "			
		Roseletal. The	European Cardiologis	t Journal by Fax,			
				March 24,2004			
			×				
• • • • • • • • • • • • • • • • • • • •		·		·			
i							
	·						

EXAMINER SIGNATURE:	1.	Saidha	<u> </u>	DATE CONSIDERED:	6	10	105

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.